Raffit Hassan
National Cancer Institute (NCI) · National Institutes of Health (NIH)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Raffit Hassan as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:26 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06885697 · Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaNational Cancer Institute (NCI) · recruiting · Mesothelioma, Neoplasms, Stomach Neoplasms · principal investigator
- Ph1NCT04840615 · Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant MesotheliomaNational Cancer Institute (NCI) · terminated · Mesothelioma · principal investigator
- N/ANCT03830229 · Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1National Cancer Institute (NCI) · recruiting · Mesothelioma, Families · principal investigator
- Ph2NCT03644550 · Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant MesotheliomaNational Cancer Institute (NCI) · terminated · Mesothelioma · principal investigator
- Ph2NCT03531840 · Olaparib in People With Malignant MesotheliomaNational Cancer Institute (NCI) · completed · Mesothelioma · principal investigator
- Ph1NCT03436732 · Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal MesotheliomaNational Cancer Institute (NCI) · terminated · Mesothelioma · principal investigator
- Ph2NCT02839681 · Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung AdenocarcinomaNational Cancer Institute (NCI) · terminated · Lung Neoplasms · principal investigator
- Ph1NCT02798536 · Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant MesotheliomaNational Cancer Institute (NCI) · completed · Mesothelioma · principal investigator
- N/ANCT01950572 · Tissue Procurement and Natural History Study of Patients With Malignant MesotheliomaNational Cancer Institute (NCI) · recruiting · Thymoma, Stomach Neoplasms, Pancreatic Neoplasms · principal investigator
- Ph1NCT01675765 · Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural MesotheliomaAduro Biotech, Inc. · completed · Malignant Pleural Mesothelioma · principal investigator
- Ph1NCT01521325 · A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing CancersMorphotek · completed · Mesothelioma, Pancreatic Cancer, Ovarian Cancer · principal investigator
- Ph1NCT01445392 · SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural MesotheliomaNational Cancer Institute (NCI) · terminated · Mesothelioma · principal investigator
- Early Ph1NCT01413451 · Amatuximab for High Mesothelin CancersNational Cancer Institute (NCI) · terminated · Carcinoma, Pancreatic Ductal, Mesothelioma, Ovarian Neoplasms · principal investigator
- Ph1/Ph2NCT01362790 · SS1P and Pentostatin Plus Cyclophosphamide for MesotheliomaNational Cancer Institute (NCI) · completed · Mesothelioma, Adenocarcinoma of Lung, Pancreatic Neoplasms · principal investigator
- Ph2NCT01160458 · Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With ChemotherapyNational Cancer Institute (NCI) · completed · Pleural Mesothelioma, Peritoneal Mesothelioma · principal investigator
- Ph1NCT00066651 · Immunotoxin Therapy in Treating Patients With Advanced Solid TumorsNational Cancer Institute (NCI) · completed · Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Adoptive cell therapy for malignant mesothelioma and other mesothelin expressingZIABC010816 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2009 to 2025 · $3,067,127 awarded in 2025Same name and institution; not confirmed by an ID
- Thoracic and Gastrointestinal Malignancies Branch Clinical CoreZIDBC011540 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2014 to 2025 · $968,567 awarded in 2025Same name and institution; not confirmed by an ID
- Immunotherapy for Malignant MesotheliomaZ01BC010816 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2007 to 2008 · $595,766 awarded in 2008Same name and institution; not confirmed by an ID
- Targeted Therapy of Mesothelioma and Development of BlooZ01BC010510 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2005 to 2006Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:26 UTC. The ranking covers the 200 most relevant of 47 PubMed records, and a shared surname and initials can bring in a namesake. All 47 on PubMed
- Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.Clin Cancer Res · 2007332 citationsRCR 7.4
- A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.Clin Cancer Res · 2012302 citationsRCR 7.3
- Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression.Sci Transl Med · 2013191 citationsRCR 5.3
- Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.Clin Cancer Res · 2009188 citationsRCR 4.5
- Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.Clin Cancer Res · 2010160 citationsRCR 3.5
- 157 citationsRCR 6.3
- Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial.Lancet · 2009154 citationsRCR 4.7
- Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.Clin Cancer Res · 2014153 citationsRCR 4.5
- Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.J Clin Oncol · 2018152 citationsRCR 4.3
- 141 citationsRCR 4.3